HuGE Literature Finder
Records 1-15
|
Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
European journal of cancer (Oxford, England : 1990) 2021 Jan 145 44-52. Furlanetto Jenny, Möbus Volker, Schneeweiss Andreas, Rhiem Kerstin, Tesch Hans, Blohmer Jens-Uwe, Lübbe Kristina, Untch Michael, Salat Christoph, Huober Jens, Klare Peter, Schmutzler Rita, Couch Fergus J, Lederer Bianca, Gerber Bernd, Zahm Dirk-Michael, Bauerfeind Ingo, Nekljudova Valentina, Hanusch Claus, Jackisch Christian, Link Theresa, Hahnen Eric, Loibl Sibylle, Fasching Peter |
|
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
ESMO open 2020 Dec 6 (1): 100019. Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes A A, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino |
|
Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
Gynecologic oncology 2019 May . Tomao Federica, Musacchio Lucia, Di Mauro Federica, Boccia Serena Maria, Di Donato Violante, Giancotti Antonella, Perniola Giorgia, Palaia Innocenza, Muzii Ludovico, Benedetti Panici Pierlui |
|
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
Breast cancer research and treatment 2019 Jan . Friedlaender Alex, Vuilleumier Aurélie, Viassolo Valeria, Ayme Aurélie, De Talhouet Solène, Combes Jean-Damien, Peron Julien, Bodmer Alexandre, Giraud Sophie, Buisson Adrien, Bonadona Valerie, Gauchat-Bouchardy Isabelle, Tredan Olivier, Chappuis Pierre O, Labidi-Galy S Intidh |
|
Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
Breast (Edinburgh, Scotland) 2018 May 40 141-146. Sella Tal, Gal Yam Einav Nili, Levanon Keren, Rotenberg Tal Shapira, Gadot Moran, Kuchuk Iryna, Molho Rinat Bernstein, Itai Amit, Modiano Tami Mekel, Gold Raya, Kaufman Bella, Shimon Shani Palu |
|
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
Cancer 2018 Apr 124 (7): 1374-1382. O'Reilly Eileen M, Lee Jonathan W, Lowery Maeve A, Capanu Marinela, Stadler Zsofia K, Moore Malcolm J, Dhani Neesha, Kindler Hedy L, Estrella Hayley, Maynard Hannah, Golan Talia, Segal Amiel, Salo-Mullen Erin E, Yu Kenneth H, Epstein Andrew S, Segal Michal, Brenner Robin, Do Richard K, Chen Alice P, Tang Laura H, Kelsen David |
|
BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2017 Nov . Kotsopoulos Joanne, Willows Karla, Trat Sandra, Kim Raymond H, Volenik Alexandra, Sun Ping, Narod Steven A, Boyd Jeffrey, May Taym |
|
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.
Oncotarget 2017 Oct 8 (45): 79175-79187. Lee Jung-Min, Hays John L, Chiou Victoria L, Annunziata Christina M, Swisher Elizabeth M, Harrell Maria I, Yu Minshu, Gordon Nicolas, Sissung Tristan M, Ji Jiuping, Figg William D, Minasian Lori, Lipkowitz Stanley, Wood Bradford J, Doroshow James, Kohn Elise |
|
[Chinese multicenter randomized trial of customized chemotherapy based on BRCA1 (breast cancer susceptibility gene 1)-RAP80 (receptor-associated protein 80) mRNA expression in advanced non-small cell lung cancer (NSCLC) patients].
Zhonghua zhong liu za zhi [Chinese journal of oncology] 2016 Nov 38 (11): 868-873. Wei J, Qian X P, Zou Z Y, Wang L F, Yu L X, You C W, Song Y, Lu H Y, Hu W J, Yan J, Xu X X, Chen X F, Li X Y, Wu Q F, Zhou Y, Zhang F L, Liu B |
|
Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer.
Breast cancer research and treatment 2016 Apr . Drooger Jan C, Heemskerk-Gerritsen Bernadette A M, Smallenbroek Nyrée, Epskamp Cynthia, Seynaeve Caroline M, Jager Agn |
|
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Gynecologic oncology 2015 Jun 137 (3): 386-91. Coleman Robert L, Sill Michael W, Bell-McGuinn Katherine, Aghajanian Carol, Gray Heidi J, Tewari Krishnansu S, Rubin Steven C, Rutherford Thomas J, Chan John K, Chen Alice, Swisher Elizabeth |
|
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
The Lancet. Oncology 2015 Jan 16 (1): 87-97. Oza Amit M, Cibula David, Benzaquen Ana Oaknin, Poole Christopher, Mathijssen Ron H J, Sonke Gabe S, Colombo Nicoletta, Špa?ek Ji?í, Vuylsteke Peter, Hirte Holger, Mahner Sven, Plante Marie, Schmalfeldt Barbara, Mackay Helen, Rowbottom Jacqui, Lowe Elizabeth S, Dougherty Brian, Barrett J Carl, Friedlander Micha |
|
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
The Lancet. Oncology 2013 Aug 14 (9): 882-92. Sandhu Shahneen K, Schelman William R, Wilding George, Moreno Victor, Baird Richard D, Miranda Susana, Hylands Lucy, Riisnaes Ruth, Forster Martin, Omlin Aurelius, Kreischer Nathan, Thway Khin, Gevensleben Heidrun, Sun Linda, Loughney John, Chatterjee Manash, Toniatti Carlo, Carpenter Christopher L, Iannone Robert, Kaye Stan B, de Bono Johann S, Wenham Robert |
|
The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients.
Oncology 2013 85 (5): 278-82. Huszno Joanna, Budryk Magdalena, Ko?osza Zofia, Nowara El?bie |
|
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Dec 12 (23): 7033-8. Shanley Susan, McReynolds Kate, Ardern-Jones Audrey, Ahern Roger, Fernando Indrajit, Yarnold John, Evans Gareth, Eccles Diana, Hodgson Shirley, Ashley Sue, Ashcroft Linda, Tutt Andrew, Bancroft Elizabeth, Short Susan, Smith Ian, Gui Gerald, , Barr Lester, Baildam Andrew, Howell Anthony, Royle Gavin, Pierce Lori, Easton Douglas, Eeles Rosali |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 19, 2021
- Content source: